Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-19-010432
Filing Date
2019-11-07
Accepted
2019-11-07 17:06:59
Documents
51
Period of Report
2019-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q axsm-20190930x10q.htm 10-Q 1883061
2 EX-31.1 axsm-20190930ex311954375.htm EX-31.1 12059
3 EX-31.2 axsm-20190930ex31244293f.htm EX-31.2 11281
4 EX-32.1 axsm-20190930ex321c9edf5.htm EX-32.1 5889
5 EX-32.2 axsm-20190930ex322ae61f1.htm EX-32.2 5863
  Complete submission text file 0001558370-19-010432.txt   4992858

Data Files

Seq Description Document Type Size
6 EX-101.INS axsm-20190930.xml EX-101.INS 808510
7 EX-101.SCH axsm-20190930.xsd EX-101.SCH 35831
8 EX-101.CAL axsm-20190930_cal.xml EX-101.CAL 30024
9 EX-101.DEF axsm-20190930_def.xml EX-101.DEF 79693
10 EX-101.LAB axsm-20190930_lab.xml EX-101.LAB 323703
11 EX-101.PRE axsm-20190930_pre.xml EX-101.PRE 221704
Mailing Address 200 BROADWAY, 3RD FLOOR NEW YORK NY 10038
Business Address 200 BROADWAY, 3RD FLOOR NEW YORK NY 10038 (212) 332-3241
Axsome Therapeutics, Inc. (Filer) CIK: 0001579428 (see all company filings)

EIN.: 454241907 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37635 | Film No.: 191201239
SIC: 2834 Pharmaceutical Preparations